Newron Pharmaceuticals S.p.A.

XETRA NP5.DE

Newron Pharmaceuticals S.p.A. Dividend Yield on January 14, 2025: 0.00%

Newron Pharmaceuticals S.p.A. Dividend Yield is 0.00% on January 14, 2025, a 0.00% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.
  • Newron Pharmaceuticals S.p.A. 52-week high Dividend Yield is 0.00% on January 14, 2025, which is 0.00% below the current Dividend Yield.
  • Newron Pharmaceuticals S.p.A. 52-week low Dividend Yield is 0.00% on January 14, 2025, which is 0.00% below the current Dividend Yield.
  • Newron Pharmaceuticals S.p.A. average Dividend Yield for the last 52 weeks is 0.00%.
Key data
Date Dividend Yield Free Cash Flow Yield Earnings Yield Enterprise Value (EV)
Market news
XETRA: NP5.DE

Newron Pharmaceuticals S.p.A.

CEO Mr. Stefan Weber
IPO Date July 4, 2019
Location Italy
Headquarters via Ludovico Ariosto 21
Employees 22
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 24 full-time employees. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

StockViz Staff

January 15, 2025

Any question? Send us an email